AC710 |
| Catalog No.GC18167 |
AC710 est un puissant inhibiteur de PDGFR avec des Kd de 0,6, 1,57, 1, 1,3, 1,0 nM pour FLT3, CSF1R, KIT, PDGFRα et PDGFRβ, respectivement.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1351522-04-7
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
AC710 is a potent, orally active, and selective platelet-derived growth factor receptor-family kinase inhibitor with potential anticancer activity. Its IC50 values are 1.2, 2, 7.7 and 10.5 nM for KIT, FLT3, PDGFRβ and CSF1R respectively; Kd = 1.3 nM for PDGFRα.. AC710 causes tumor regression of leukemia cell xenografts in mice. AC710 also reduces joint swelling and inflammation in a mouse model of collagen-induced arthritis. AC710 is now a preclinical development candidate.
REFERENCES:
Liu *†, Brian T. Campbell †, Mark W. Holladay †, Julia M. Ford Pulido ‡, Helen Hua ‡, Dana Gitnick , Michael F. Gardner , Joyce James , Mike A. Breider , Daniel Brigham ‡, Barbara Belli ‡, Robert C. Armstrong ‡, and Daniel K. Treiber. Discovery of AC710, a Globally Selective Inhibitor of Platelet-Derived Growth Factor Receptor-Family Kinases. ACS Med. Chem. Lett., 2012, 3 (12), pp 997–1002
Average Rating: 5 (Based on Reviews and 4 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *